Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cells for diabetic foot ulcers
NCT05595681Phase 1Terminated
- Sponsor
- Cell to Cure
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Cell2Cure in diabetic foot ulcer (DFU) (2 arms), sponsored by Cell to Cure. Primary endpoint: Time to complete ulcer healing at 12 weeks. Started Dec 2022; status: terminated.
02
Drugs
Cell2Cure
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT05595681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595681.